The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 16, 2008
Filed:
May. 01, 2005
Kevin D. Raney, Little Rock, AR (US);
Craig E. Cameron, State College, PA (US);
Bhuvanesh Dave, Little Rock, AR (US);
Joshua Sakon, Fayetteville, AR (US);
Jeff Zhiqiang LU, Towson, MD (US);
Samuel G. Mackintosh, Little Rock, AR (US);
Thomas A. Jennings, Little Rock, AR (US);
Kevin D. Raney, Little Rock, AR (US);
Craig E. Cameron, State College, PA (US);
Bhuvanesh Dave, Little Rock, AR (US);
Joshua Sakon, Fayetteville, AR (US);
Jeff Zhiqiang Lu, Towson, MD (US);
Samuel G. Mackintosh, Little Rock, AR (US);
Thomas A. Jennings, Little Rock, AR (US);
The Board of Trustees of the University of Arkansas, Little Rock, AR (US);
Abstract
The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.